Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore-Bianchi, L Trusolino, C Martino… - The Lancet …, 2016 - thelancet.com
Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
[引用][C] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer …
A Sartore-Bianchi, L Trusolino, C Martino… - The Lancet …, 2016 - cir.nii.ac.jp
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon
12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept …
12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore Bianchi, L Trusolino, C Martino… - THE LANCET …, 2016 - iris.unito.it
BACKGROUND: We previously found that dual HER2 blockade with trastuzumab and
lapatinib led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified …
lapatinib led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore-Bianchi, L Trusolino, C Martino… - The Lancet …, 2016 - thelancet.com
Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore-Bianchi, L Trusolino, C Martino… - The Lancet …, 2016 - infona.pl
We previously found that dual HER2 blockade with trastuzumab and lapatinib led to
inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore-Bianchi, L Trusolino, C Martino… - The Lancet …, 2016 - Elsevier
Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore-Bianchi, L Trusolino… - The Lancet …, 2016 - pubmed.ncbi.nlm.nih.gov
Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore Bianchi, L Trusolino, C Martino… - THE LANCET …, 2016 - iris.unicampania.it
BACKGROUND: We previously found that dual HER2 blockade with trastuzumab and
lapatinib led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified …
lapatinib led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore-Bianchi, L Trusolino, C Martino… - The Lancet …, 2016 - europepmc.org
Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …